Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. [electronic resource]
Producer: 20030121Description: 3676-85 p. digitalISSN:- 1078-0432
- Adenocarcinoma -- prevention & control
- Adult
- Aged
- Antibodies, Viral -- immunology
- Carcinoma, Squamous Cell -- prevention & control
- DNA, Viral -- metabolism
- DNA-Binding Proteins
- Female
- Genotype
- HLA-A1 Antigen -- metabolism
- Humans
- Immunoenzyme Techniques
- Middle Aged
- Neoplasm Staging
- Oncogene Proteins, Viral -- genetics
- Papillomaviridae -- immunology
- Papillomavirus E7 Proteins
- Papillomavirus Infections -- prevention & control
- Papillomavirus Vaccines
- Phenotype
- Polymerase Chain Reaction
- Polymorphism, Single-Stranded Conformational
- Repressor Proteins
- Seroepidemiologic Studies
- T-Lymphocytes, Cytotoxic -- immunology
- Tumor Virus Infections -- prevention & control
- Uterine Cervical Neoplasms -- prevention & control
- Vaccination
- Vaccines, Synthetic
- Vaccinia virus -- genetics
- Viral Vaccines -- therapeutic use
- Uterine Cervical Dysplasia -- prevention & control
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.